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ABSTRACT
Cholesterol 7a hydroxlyase (CYP7A1) is a key
enzyme in cholesterol catabolism to bile acids and
its activity is important for maintaining appropr-
iate cholesterol levels. The murine CYP7A1 gene is
highly inducible by thyroid hormone in vivo and
there is an inverse relationship between thyroid
hormone and serum cholesterol. Eventhough gene
expression has been shown to be upregulated,
whether the induction was mediated through a
direct effect of thyroid hormone on the CYP7A1
promoter has never been established. Using gene
targeted mice, we show that either of the two TR
isoforms are sufficient to maintain normal hepatic
CYP7A1 expression but a loss of both results in a
significant decrease in expression. We also identi-
fied two new functional thyroid hormone receptor-
binding sites in the CYP7A1 50 flanking sequence
located 3 kb upstream from the transcription start
site. One site is a DR-0, which is an unusual type
of TR response element, and the other consists of
only a single recognizable half site that is required
for TR/retinoid X receptor (RXR) binding. These two
independent TR-binding sites are closely spaced
and both are required for full induction of the
CYP7A1 promoter by thyroid hormone, although
the DR-0 site was more crucial.
INTRODUCTION
Cholesterol 7a hydroxlyase (CYP7A1) catalyzes the initial
and rate-limiting step in the neutral synthetic pathway of
bile acids from cholesterol. Because the bile acid synthetic
pathway is a major route to remove excess cholesterol from
the body, CYP7A1 is considered an important enzyme in cho-
lesterol homeostasis (1). CYP7A1 is exclusively expressed
in the liver and the gene is subject to metabolic regulation
by oxysterols, bile acids, hormones, nutrients and cytokines.
In mice and rats, CYP7A1 is activated by cholesterol excess
through by product oxysterols that function as ligand agonists
for the liver X receptor (LXR)/retinoid X receptor (RXR) het-
erodimer which binds to direct repeats of half sites separated
by 4 nt (DR-4, LXRE) in the CYP7A1 promoter, increasing
expression of CYP7A1 (2–4). Conversely, bile acids inhibit
CYP7A1 gene expression through a negative feed back
mechanism operating through several molecular pathways.
In one pathway, bile acids activate the farnesoid X receptor
(FXR), which in turn induces expression of the small het-
erodimer partner (SHP). SHP binds to and interferes with
the activity of the a1-fetoprotein transcription factor (FTF-1,
also called LRH-1), leading to an inhibition of CYP7A1
expression (5,6). Hepatocyte nuclear factor 4 (HNF-4) has
also been shown to mediate bile acid-induced repression of
CYP7A1 (7). In fasted mouse livers and in type I diabetic
mice, PPAR-g-coactivator one alpha (PGC-1a) plays an
important role in activating CYP7A1 gene expression (8).
Additionally, CYP7A1 expression is regulated by thyroid
hormone through a direct effect on gene transcription (9–11).
Thyroid hormone mediates its action through the thyroid
hormone receptor (TR), a member of the nuclear receptor
superfamily of ligand-dependent transcription factors (12,13).
There are two major isoforms of TR generated by different
genes, TRb and TRa. Each isoform exhibits a distinct pattern
of tissue and developmental expression and there are multiple
transcripts from each TR gene. TRb is the primary isoform in
the liver (14). TR binds to speciﬁc DNA sequences, TR
response elements (TREs), as monomers, homodimers, or
with RXR in a heterodimer. Since RXR enhances the binding
afﬁnity of TR to TRE, TR/RXR heterodimers have been
suggested to be major protein complexes that mediate thyroid
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synthetic DNA and in vitro DNA-binding studies, a high
afﬁnity consensus element for TR was determined to be the
DR-4 motif (16). However, naturally occurring TREs diverge
signiﬁcantly from this consensus and many consist of differ-
ent orientations and conﬁgurations of repeats of the nuclear
receptor half site AGGTCA half site. This can vary from a
single half site (17) to a DR-0 (18), palindromes (17,19)
and multiple separate and variably spaced direct repeats
(20,21).
The association of hypothyroidism with hypercholester-
olemia was ﬁrst recognized in 1930 (22,23). This thyroid
hormone effect is thought to be through direct regulation of
target genes of cholesterol metabolism at the transcriptional
level (9–11). Cholesterol homeostasis is maintained through
cooperative regulation of cholesterol uptake and de novo
synthesis together with cholesterol catabolism to bile acids
(1). Accordingly, our previous studies have shown that thyr-
oid hormone directly up-regulates expression of sterol regu-
latory element binding protein-2 (SREBP-2), which in turn
increases expression of low density lipoprotein receptor
(LDLR), resulting in a decrease in plasma cholesterol
levels (24).
Cholesterol catabolism is also modulated by thyroid
hormone primarily through changes in CYP7A1 mRNA
levels. CYP7A1 mRNA is induced rapidly within 1 h of
triiodothyronine (T3) treatment in hypophysectomized rats
(10,11) and T3 treatment also increases the rate of
CYP7A1 gene transcription (9). This rapid induction suggests
that the increase in CYP7A1 mRNA may be directly medi-
ated by thyroid hormone at the transcriptional level. In addi-
tion, induction of CYP7A1 expression by T3 was blunted in
TRb knockout mice (25) and knock-in mice where a mutant
TRb was inserted that has a defect in ligand binding (26).
These studies argue strongly for a direct action of TR on
CYP7A1. Indeed, protein–DNA-binding studies have shown
direct binding of TR/RXR to the proximal DR-4 of the
CYP7A1 promoter which has been characterized as an
LXRE (26). However, whether this proximal site or any
other TR-binding site(s) in the promoter is responsible for
TR responsiveness has not been established. In the current
study, we have identiﬁed two closely spaced TREs in the far
upstream region of the CYP7A1 promoter that are respons-
ible for the CYP7A1 stimulation by T3. Both these TRE
were required for full induction of T3 and unlike some
TREs, these CYP7A1 T3 response elements do not respond
to LXR signaling.
MATERIALS AND METHODS
Animal treatments
All animals used in this study were acquired and maintained
in accordance with the NIH Guide for the Care and Use of
Laboratory Animals. For studies at UC Irvine, the protocols
were approved by the campus IACUC committee (approval
97-1545). For studies in Lyon, mice were housed, maintained
and sacriﬁced with approval from the animal experimental
committee of the Ecole Normale Supe ´rieure de Lyon and in
accordance with the ‘Commission de Ge ´nie Ge ´ne ´tique’
(Agreement number 12837).
The 4-week-old B6129 male mice were obtained from
Taconic and maintained on a 12 h light/dark cycle with
free access to food and water. The mice were allowed to
adapt to the new environment for 1 week before experiments.
Thyroid hormone deﬁciency was induced by feeding a low-
iodine diet supplemented with 0.15% propylthiouracil
(PTU) (Harlan Teklad) for 3 weeks, as described previously
(24). For the thyroid hormone-supplemented group, mice
were given 1 mg of T3 (ICN) per gram of body weight on
the 18th day of the low-iodine diet with PTU by intraperiton-
eal injections daily for 4 days. The control group was fed
ad libitum with normal chow diet. The mice were sacriﬁced
between 8:00 and 10:00 a.m. Livers were removed and
frozen in liquid nitrogen and stored at  80 C until RNA
was isolated.
For the studies in TR knockout mice, 8- to 10-week-old
TRa
0/0 (27), TRb
 /  (28), TRa
0/0/TRb
 /  (28) and the res-
pective wild-type control animals were used in this study.
They were maintained on a 12 h day/12 h dark schedule
(light on at 7 a.m.) and fed standard mouse chow and water
ad libitum. For the experiments, animals were sacriﬁced at
2 p.m. after 4 h of starving. The liver was quickly removed
and frozen in liquid nitrogen and used for RNA extraction.
RNA isolation and northern blot analysis
Total RNA was isolated from mouse livers using TRIzol
(invitrogen). Total RNA (20 mg) from two to four individual
animals per feeding condition was subjected to northern
analysis with
32P-labeled probes as described previously
(24). Expression of ribosomal protein L32 was measured
as a control to normalize signals from different lanes. The fol-
lowing cDNA probes were used: CYP7A1 (a gift from G. Gil,
Virginia Commonwealth University), a 0.7 kb AccI/EcoRI
fragment from the pBSK7a; 50DI, a 0.8 kb BamHI/EcoRI
from pCR2.1-mouse 50DI, and a 80 base HindIII/EcoRI
fragment of rat ribosomal protein L32 cDNA (24).
Cell culture and transient transfection assay
HepG2 cells were cultured at 37 C and 5% CO2 in minimal
essential medium supplemented with 10% fetal bovine serum
(FBS) and penicillin/streptomyocin. Transient transfections
were performed by the calcium phosphate co-precipitation
method, as described previously (24). Brieﬂy, cells were
seeded in 6-well dishes at 350000 cells/well one day before
transfection. The next day (16 h later), cells were transfected
with 2 mg/well of the indicated CYP7A1 luciferase reporter
and 2 mg/well of cytomegalovirus b-galactosidase plasmid
as an internal control for transfection efﬁciency. Expression
vectors for CMX-hTR-b (2 mg), CMX-LXRa (0.5 mg) and
CMX-hRXRa (0.5 mg) were included as indicated in the
ﬁgures. Equal amounts of DNA were used for all transfection
reactions by adding empty vector DNA. After 4–6 h, cells
were treated with 10% glycerol for 2 min, washed three
times with phosphate-buffered saline (PBS), and refed with
a serum-free medium supplemented with 5 mg/ml insulin,
5 mg/ml transferrin, 5 ng/ml selenite, 5 ml/ml deﬁned lipid
mix and 0.1% de-lipidated BSA (Sigma) in the presence or
absence of 1 mM 3,30T3. Cells were incubated for additional
40 h and harvested for luciferase and b-galactosidase assays
and normalized expression was determined as described
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Plasmids
The region corresponding to  7454/+59 of the rat CYP7A1
promoter was obtained from pR7a-Cat9 (a gift from G. Gil,
Virginia Commonwealth University) by digestion with SalI
and XbaI and inserted into the XhoI and NheI sites of
pGL3 basic to generate pGL3R7a-7454. pGL3R7a-3640
was constructed by digestion of pGL3R7a-7454 with
SacI followed by re-ligation. To construct pGL3R7a-1667,
pGL3R7a-3640 was digested with SacI and PstI, and blunted
by T4 polymerase, and re-ligated. A series of 50-deletion
mutants of pGL3R7a-3640 was constructed by PCR-based
ampliﬁcation. The following forward primers were
used:pGL3R7a-3382,50-GTGAACTTTCCTGTATGGGT-30;
pGL3R7a-3132, 50-TGGTATGCCAGGACTTTGGA-30; and
pGL3R7a-3008, 50-ACTTCAGTGCCCACCATGCA-30. The
reverse primer for all was 50-ACAAGTAGACTGCAA-
GGGGA-30. The SacI site was added to the forward primer
for cloning purpose. Because the PCR fragments include the
SmaI site at  2770 bases, they were digested with SacI and
SmaI and inserted into the SacI and SmaI sites of
pGL3R7a-3640 to generate pGL3R7a-3382, pGL3R7a-
3132 and pGL3R7a-3008. pGL3R7a-3640mTRE1, pGL3R7a-
3132mTRE1, pGL3R7a-3132mTRE2 and pGL3R7a-
3132mTRE1/2 were constructed by site-directed mutagenesis
(QuikChange, Stratagene). The sequences of one strand
of the complementary primers are shown below: mTRE1, 50-
CAATAATAACCCTGTCTTTTCAAAGCATCTATCTGT-
ACTGCTGC-30; and mTRE2, 50-CTGCTGCAATAGAAAC-
TCCACAGGTCAAAATCACAGCTGTTGTGT-30.
To generate pGL3R7a-3132/342, a fragment from  3132
to  3008 was produced by PCR. The forward primer was the
same as the one for pGL3R7a-3132. The reverse primer was
50-AATCCTGGGGACACTGTGTA and included the XbaI
site for cloning purpose. The PCR fragment was digested
with SacI and XbaI and inserted into the SacI and NheI
sites of pGL3R7a-342. CMX-hTR-a and CMX-hTR-b were
from Dr Bruce Blumberg, University of Califormia, Irvine,
and CMX-hRXR-a and CMX-LXRa were from Dr Peter
Tontonoz (UCLA).
Electrophoretic mobility shift assays
Human TRa,T R b and RXRa proteins were synthesized
using the TNT-coupled transcription/translation system
(Promega). The sequences of one strand of the complement-
ary oligonucleotide probes are as follows: wild-type TRE1,
50-AACCCTGTCTTTTCAGGGCATCTATCTGTACTGCT-
GCAATAGAAA-30; mutant TRE1, 50-AACCCTGTCTTTTC
AAAGCA TCTA TCTGTA CTGCTGCAATAGAAA-30;
wild-type TRE2, 50-AATAGAAACTCCACAGGTCA GGG-
TCA CAGCTGTTGTGTTTTACACA-30; mutant TRE2,
AATAGAAACTCCAC AGGTCAAAATCACAGCTGTTG-
TGTTTTACACA-30; and DR-4, 50-CTAGAGCTTCAGGT-
CACAGGAGGTCAGAGAGCT-30. The complementary
oligonucleotides were annealed, and where indicated, they
were labeled with [g-
32P]ATP by T4 polynucleotide kinase.
Protein–DNA-binding assays were performed as described
previously (24). For competition experiments, unlabeled
probes were included in the binding buffer at the concentra-
tion indicated in the legend to Figure 3B and C.
Chromatin immunoprecipitation assays (ChIP)
Rat hepatoma H4IIE cells were grown to 70% conﬂuence in
minimum essential medium supplemented with 10% FBS at
37 C and 5% CO2. Nuclear proteins were crosslinked to
DNA by adding formaldehyde to the culture medium to a
ﬁnal concentration of 1% for 5 min at room temperature.
Crosslinking was stopped by adding glycine to a ﬁnal concen-
tration of 0.125 M for 10 min. Cells were washed three times
and collected in ice-cold PBS supplemented with protease
inhibitors. Cell pellets were resuspended in lysis buffer
(5 mM HEPES, pH 8.0, 85 mM KCl, 0.5% NP-40 and
protease inhibitors) and homogenized with ﬁve strokes of a
dounce homogenizer with a B pestle to release nuclei. After
centrifugation at 313·g for 10 min at 4 C, nuclear pellets
were resuspended in nuclear lysis buffer (50 mM Tris–HCl,
pH 7.6, 10 mM EDTA, 1% SDS and protease inhibitors)
and sonicated for 5 min with 30 s on/off intervals to reduce
the size of chromatin to  500 bases in length (monitored
by gel electrophoresis). Lysates were diluted 1:20 in IP dilu-
tion buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris–HCl, pH 7.6, 167 mM NaCl and protease
inhibitors). Crosslinked chromatin samples were precleared
by adding salmon sperm DNA–protein G agarose slurry and
mouse IgG for 2 h at 4 C with rotation. Supernatants were
recovered and incubated with 5 ml of anti-TRb (Afﬁnity
BioReagents, Golden, CO) or mouse IgG overnight at 4 C
with rotation. The immune complexes were then mixed
with salmon sperm DNA–protein G agarose slurry for 2 h
at 4 C with rotation. The beads were collected by microspin
column and washed sequentially with the following buffers:
buffer B (20 mM Tris–HCl, pH 7.6, 2 mM EDTA, 0.05%
SDS, 1%Triton X-100 and 150 mM NaCl), buffer D (20
mM Tris–HCl, pH 7.6, 2 mM EDTA, 0.05% SDS, 1% Triton
X-100 and 500 mM NaCl), buffer 3 (10 mM Tris–HCl, pH
7.6, 250 mM LiCl, 1 mM EDTA, 1%
NP-40 and 1% deoxycholate) and IP wash buffer (20 mM
Tris–HCl, pH 7.6, 150 mM NaCl, 2 mM EDTA and 1%Triton
X-100). The immune complexes were eluted with IP elution
buffer (40 mM sodium bicarbonate and 1% SDS). After
reversing the protein–DNA crosslinks in the chromatin,
DNA was recovered by Qiagen PCR purication kit and
used as a template for quantitative PCR with an I-cycler
(Bio-Rad). Supernatants from immunoprecipitation with IgG
were saved and used to prepare control samples representing
the unenriched starting material or ‘input’ DNA. A series of
dilutions of input DNA with known concentrations (OD260)
was used as a template to monitor the efﬁciency of quantitat-
ive PCR and to quantify DNA croslinked to TR protein. The
following primers were used for quantitative PCR: rCYP7A1
TREs forward 50-AAACTCAACTTGGTATGCCAGGAC-30;
rCYP7A1 TREs reverse 50-TCACACACATGCACACAAG-
CAC-30; rCYP7A1 DR-4(LXRE) forward 50-AGCACATGA-
GGGACAGACCTTCAG-30; rCYP7A1 DR-4(LXRE) reverse
50-TGCACAGGACCATGATCCAATAAC-30; rYY1 exon
4 forward 50-GCTGCACAAAGATGTTCAGGGATAA-30;
and rYY1 exon 4 reverse 50-CTGAAAGGGCTTTTCTCCA-
GTATG-30.
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Thyroid hormone induces CYP7A1 mRNA in vivo
Expression of the murine CYP7A1 gene ﬂuctuates in
response to thyroid hormone status (9–11). This is demon-
strated in Figure 1A where CYP7A1 mRNA was barely
detectable in livers of thyroid hormone depleted mice but
was signiﬁcantly induced when T3 was added back after
the depletion. The 50 deiodinase gene, a well-known target of
thyroid hormone (29), displayed a similar response to T3. As
the mice were treated with supraphysiological doses of T3 to
induce hyperthyroid conditions (30) mRNA levels for
CYP7A1 and 50 deiodinase in mice treated with T3 were
hyperactivated relative to control mice. To investigate the
regulation of CYP7A1 by T3 further we evaluated expression
in knockout mice that totally lack each or both of the TR iso-
forms. When these animals were fed normal chow diets with-
out manipulating the thyroid hormone content, CYP7A1
mRNA was elevated in livers from TRa knockout mice and
only when both TR receptors are disrupted was there a
notable reduction in basal CYP7A1 mRNA (Figure 1B,
P ¼ 0.026). In contrast, expression of the 50 deiodinase
gene was sensitive to the speciﬁc loss of the TRb isoform.
These results indicate that either TR isoform can activate
CYP7A1 whereas the 50 deiodinase gene is preferentially
activated by TRb (Figure 1B).
Taken together with previous studies, these results suggest
that CYP7A1 is a direct thyroid hormone target gene; how-
ever, a T3 response element had not been located previously.
Therefore, a fragment of the 50-ﬂanking region of the rat
CYP7A1 promoter from  3640 to +59 (pGL3R7a-3640)
was fused to the luciferase reporter gene and tested for T3
responsiveness in co-transfection assays in HepG2 cells.
The HepG2 cell-based co-transfection assay has been estab-
lished to evaluate T3 regulation of other genes (24). In this
assay, expression vectors for TRb and RXRa were
co-transfected with pGL3R7a-3640 into HepG2 cells that
were subsequently cultured in the presence or absence of T3
and the activity of the reporter gene was measured. As shown
in Figure 2A, T3 treatment resulted in a 21-fold increase in
the activity of pGL3R7a-3640. In contrast, when T3 was
added without the expression constructs or if the TRb and
RXRa expression vectors were added without T3, there was
only minimal promoter activity. As a control, the activity
Figure 2. CYP7A1 promoter is activated by TR in response to T3.
(A) HepG2 cells were transfected with the indicated promoter–luciferase
fusion construct and where indicated expression vectors were added for
TRb and RXRa. Cells were cultured in serum-free minimal medium and
1 mM T3 was added as indicated and described in Materials and
Methods. Results are expressed as corrected luciferase light units divided
by the internal control signal for b-galactosidase activity. (B) Similar
experiments were performed in HepG2 cells with the indicated promoter–
luciferase fusion construct along with expression vectors for TRb and
RXRa. The fold (x) change in the promoter activity by T3 relative to
cells transfected with each luciferase reporter alone is shown beside each bar.
The data from (A) and (B) represent the mean of duplicates for three
individual experiments and include error bars (SEM). RLU, relative light
units.
Figure 1. Thyroid hormone regulation of the CYP7A1 gene. (A) Total RNA
was isolated from livers of mice that were fed a normal chow (C), an iodine-
deficient diet supplemented with PTU (P) or an iodine-deficient diet
supplemented with PTU and injected with T3 (P+T3). Equal amounts
(20 mg) of total RNA from individual animals was loaded in separate lanes
and analyzed by northern analysis to measure mRNA levels for CYP7A1 and
50DI. Signals were quantified using Quantity One software from Bio-Rad
using densitometric scans from autoradiograms, and the intensities were
normalized relative to the control ribosomal protein L32 mRNA for each
lane. Results are expressed as a fold change relative to the value from the
control chow-fed animals. The mean values obtained from individual
measurements from six animals in each group are shown with error bars.
(B) Total RNA was isolated from livers of WT, TRa(0/0), TRb( / ) and
TRa(0/0)/TRb( / ) that were fed a normal chow.
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a known T3 responsive promoter (31), was also activated
signiﬁcantly in response to T3 in these studies. These data
suggest that the CYP7A1 promoter is T3 responsive and
that TRE(s) directly mediating the response are located
within the 3640 bases ﬂanking the 50 end of the transcription
start site.
To identify the TRE(s), a series of progressive 50 deletions
of the promoter were prepared and tested for T3 respons-
iveness as above. Truncation from  3640 to  3382, or to
 3132 caused no signiﬁcant change in T3 responsiveness
(Figure 2B). However, deletion to  3008 resulted in a
marked decrease in T3 activation from 24.8- to 3.9-fold.
Further deletion down to  1667 showed a modest drop of
T3 activation to 2- to 3-fold of the basal promoter activity
observed in pGL3R7a-342. A modest increase in promoter
activity by 2- to 3-fold has been shown for the empty
pGL3-basic vector in the presence and absence of T3 (24)
and was not considered to represent speciﬁc T3 response.
These results suggest that a T3 responsive region is located
at 3000 bp 50 to the CYP7A1 mRNA start site.
Identification of thyroid hormone receptor-binding
sites in the CYP7A1 promoter
Using synthetic response and binding elements, it was shown
that TR preferentially binds to a site containing two direct
repeats of hexameric half sites of AGGTCA spaced by 4 nt.
However, naturally occurring TR-binding sites are diverse
with respect to the sequence and orientation of the half sites,
and the number of nucleotides in the spacer (12,15). When we
scanned the  3000 region of the promoter for nuclear
receptor half sites, two DR motifs were found: one consisting
of a single half site, designated TRE1, and the other consist-
ing of a single half site, designated TRE2 (Figure 3A).
Importantly, although the sequence of the mouse and rat
promoters diverge signiﬁcantly in this region of the promoter,
the TRE1 is moderately conserved and TRE2 is exactly
identical.
To evaluate whether these putative TREs directly bind TR,
gel shift assays were performed using
32P-labeled oligo-
nucleotides containing either TRE1 or TRE2 with in vitro
translated TRa,T R b and RXRa protein. Heterodimers of
both TRa/RXRa or TRb/RXRa formed complexes with
Figure 3. Identification of TR/RXR-binding sites in the CYP7A1 promoter. (A) The 50-flanking sequence alignment of the rat and mouse CYP7A1 promoter is
shown. Arrows indicate putative TREs. (B) In the upper panel, the sequence of the wild-type TRE1 is presented as TRE1/WT. The sequence of mutations in
TRE1 is indicated with lower case lettering with mTRE1. The full sequences for the oligonucleotide probes are detailed in Materials and Methods. An
autoradiogram from a representative gel shift assay is shown in the lower panel.
32P-labeled probes were incubated with in vitro translated TRa,T R b and RXRa,
as indicated. Where indicated, a 100-fold molar excess of the indicated unlabeled probe (Comp.) was included in the binding reactions with the labeled probe. D4
denotes the consensus DR-4. WT and M1 denote the wild-type TRE1 and mutant TRE1, respectively. The arrow denotes the position of specific protein–DNA
complexes. (C) Similar experiments were performed for TRE2 as described in (B).
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(Figure 3B and C, lanes 5 and 6). A 100-fold molar excess
of unlabeled wild-type TRE1 or a consensus TRE, DR-4
(32), efﬁciently competed out TRb/RXRa for binding to
TRE1 (lanes 7 and 8). A 2-base mutation in the 50 half site
of either TRE disrupted binding of TRb/RXRa with DNA
(lanes 13 and 14). Consistently, unlabeled mutant probe
(mTRE1 or mTRE2) was not able to compete out TRb/
RXRa for the binding to the respective TRE (lane 9) and sim-
ilar protein–DNA complexes were observed for the consensus
DR-4 site that was used as a positive control. Taken together,
these results suggest that TR/RXR binds independently to
both TRE1 and TRE2.
TRE1 and TRE2 are responsible for the TR
response of CYP7A1
To determine whether TRE1 or TRE2 contribute to the T3
stimulation of the CYP7A1 promoter, point mutations identi-
cal to the bases mutated in the gel shift assays were intro-
duced into either the TRE1 or TRE2 or both simultaneously
in the pGL3R7a-3640 and pGL3R7a-3132 reporter plasmids
by site-directed mutagenesis. The mutant constructs were
then examined for T3 responsiveness as described in
Figure 2. A mutation in TRE1 of pGL3R7a-3640 caused a
61% decrease in T3 response (Figure 4A), compared to its
respective wild-type promoter, but it retained a signiﬁcant
amount of the T3 response. Similarly, mutation of TRE1 of
pGL3R7a-3132 reduced T3 mediated-promoter activity by
46%, compared to its respective wild-type promoter. When
a mutation was introduced into the TRE2, the mutant con-
struct displayed almost no response to T3. The complete
loss of T3 responsiveness was also observed for the TRE1/
TRE2 double mutant. These data suggest that both of the
TREs contribute to the T3 responsiveness, although TRE2
appears to be more critical.
To test the ability of these speciﬁc TREs to confer T3
stimulation to an otherwise non-responsive promoter the
short region containing  3132 to  3008 that harbors both
TREs was ligated to pGL3R7a-342 to generate pGL3R7a-
3132/342. As shown in Figure 4B, addition of this small frag-
ment containing both TREs to the  342 promoter resulted in
an 18-fold increase in response to T3 which was similar to the
full-length  3640 construct. As expected, expression from
the simple pGL3R7a-342 construct was insensitive to T3.
TRE1/TRE2 do not mediate an LXR response
Because TR and LXR both prefer binding to DR-4 elements
(33) and because there is a DR-4 in the proximal murine
CYP7A1 promoter that is responsive to LXR signaling (3),
we evaluated whether these newly identiﬁed TREs might
also contribute to LXR activation of CYP7A1. pGL3R7a-
3132/WT, pGL3R7a-3132/mTRE1,2 or pGL3R7a-3008/WT
were co-transfected with expression vectors for LXRa and
RXRa in the presence or absence of GW3695, a synthetic
agonist for LXR. The results from these experiments were
compared with those for T3 responsiveness of the same con-
structs. As shown in Figure 5, the potent stimulation by LXR
was not affected by mutations in or loss of either TRE1 or
TRE2.
Figure 5. The TRE1/TRE2 do not mediate an LXR response. HepG2 cells
were transfected with the indicated promoter–luciferase fusion construct and
where indicated expression vectors for TRb/RXRa or LXRa/RXRa were
also included. Cells were cultured in serum-free minimal medium in the
presence or absence of 1 mMT 3o r5mM GW3695. Results are expressed as
normalized luciferase light units divided by b-galactosidase activity. The
25-fold activation by T3 for the pGL3R7a-3132/WT construct was set to
100%. The magnitude of the T3 response of pGL3R7a-3132/mTRE1,2 and
pGL3R7a-3008/WT is presented relative to that of pGL3R7a-3132/WT.
The 30-fold activation of pGL3R7a-3132/WT by GW3695 relative to cells
transfected with luciferase reporter alone was set to 100%. The magnitude of
the GW3695 response of pGL3R7a-3132/mTRE1,2 and pGL3R7a-3008/WT
was presented relative to that of pGL3R7a-3132/WT. The data represent the
mean of duplicates for three individual experiments and include error bars.
Figure 4. TRE1 and TRE2 are responsible for the TR response of CYP7A1.
(A) Transfection assays with wild-type and the indicated mutant luciferase
reporter constructs were performed in cultured HepG2 cells as described in
the legend to Figure 3. The data represent the mean of duplicate samples for
three individual experiments and include error bars. M1 and M2 denote
mutants of TRE1 and TRE2, respectively, where the identical nucleotide
substitutions used to disrupt TR binding in Figure 3B and C were introduced
into TRE1 or/and TRE2 of the luciferase reporter constructs. (B) The
sequence from  3132 to  3008 was fused to the  342 sequence of the
truncated CYP7A1 promoter reporter construct and compared to the full-
length and  342 truncated promoter construct for T3 responsiveness as
described in (A).
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To directly evaluate if TRb is capable of binding the TREs of
the CYP7A1 promoter on the endogenous CYP7A1 gene in
cellular chromatin, a ChIP study was performed in H4IIE
cells. These cells have been used as a useful system to study
regulation of gene expression by thyroid hormone (34) and
has been used successfully to demonstrate that TR binds to
TR target genes using the ChIP technique. Because TR has
been shown to bind in chromatin in the presence or absence
of its ligand (35), we made chromatin from H4IIE cells cul-
tured under normal conditions without T3. After crosslinking
with formaldehyde, aliquots were immunoprecipitated with
anti-TRb or a control mouse IgG fraction and binding to
speciﬁc chromatin sites was analyzed by a quantitative PCR
protocol. As shown in Figure 6, TRb was efﬁciently recruited
to the  3000 region of the CYP7A1 promoter (8-fold com-
pared to a non-speciﬁc IgG control). Although the proximal
DR-4 does not mediate a T3 response, TR was shown to be
recruited to this proximal LXR responsive DR-4 in a previous
study (26,36). Therefore, we also evaluated TR binding to the
proximal promoter as well where a modest 2-fold binding
enrichment of TR was observed. As a negative control, TR
binding to a non-relevant region of the genome was also
evaluated and shown to be negative (the YY1 locus). These
data demonstrate that TRb is speciﬁcally recruited to the
 3000 TREs of the CYP7A1 promoter in cellular chromatin
where the two TREs identiﬁed in our study are located.
DISCUSSION
Thyroid hormone inﬂuences many aspects of hepatic
metabolism, and the rate controlling enzyme of neutral bile
acid metabolism, CYP7A1, was shown to be activated at
the transcriptional level by thyroid hormone in vivo in previ-
ous studies (9–11). However, no functional TRE(s) capable of
conferring T3 responsiveness to CYP7A1 had been identiﬁed
previously. Using transient transfection assays and DNA-
binding studies, we have identiﬁed two TREs that are
responsible for the T3 stimulation of the murine CYP7A1
gene. The two TREs are closely spaced and located in a far
upstream region of the promoter at 3 kb upstream relative
to the transcription start site.
TREs are generally found in the proximal region of
promoters, as for the rat growth hormone (17,19), rat malic
enzyme (20), myelin basic protein (37) and a-myosin
heavy chain genes (38). However, there are some TREs
that are located in a far upstream 50 region. For example,
the TREs of the rat Spot 14 and chicken malic enzyme
genes are located 2.7 and 3.8 kb upstream of the respective
transcription start sites, respectively (39,40). These natural
TREs are often clustered and arranged with multiple repeats
of the half site, functioning synergistically or cooperatively.
Similarly, the two closely spaced TREs are located 3 kb
upstream from the CYP7A1 mRNA start site and are both
necessary for full responsiveness to T3, although the TRE2
plays a more crucial role in T3 stimulation (Figure 4).
We also examined the recruitment of TRb to the TREs
and DR-4 (LXRE) of the endogenous CYP7A1 in H4IIE
cells. Our ﬁnding of greater recruitment of TRb to the
 3 kb TREs compared to the proximal DR-4 (LXRE) is con-
sistent with the data from transfection assays where the distal
TREs mediate a strong T3 response. This would likely occur
when the afﬁnity of TR binding simply reﬂects the functional
augmentation of the T3 response. It is also possible that LXR
may be more abundant than TR in H4IIE cells such that the
DR-4 (LXRE) may be preferentially occupied by LXR/RXR
rather than TR/RXR. Regardless, the presence of the prox-
imal DR-4 is not sufﬁcient to provide a signiﬁcant response
to T3 stimulation.
We have also shown that either TRa or TRb appears
sufﬁcient for normal expression of CYP7A1 when animals
are euthyroid and maintained on a chow diet (Figure 1). How-
ever, when both receptors are gone there is a signiﬁcant
decrease in CYP7A1 mRNA. In contrast, expression of the
50 deiodinase gene speciﬁcally requires TRb under these
conditions. Thus, either TR isoform appears capable of
sustaining basal CYP7A1 expression. It is important to note
that earlier reports showed that TRb was key to activating
CYP7A1 under dietary and pharmacological manipulation
that dramatically alter thyroid hormone levels (25,41).
There is a signiﬁcant increase in CYP7A1 mRNA in the
TRa knockout mice suggesting that this receptor may func-
tion as a negative regulator of CYP7A1 when TRb is also
Figure 6. Recruitment of TRb to the CYP7A1 TREs in H4IIE cells.
Chromatin was prepared from H4IIE cells grown under normal conditions.
The ChIP assays were performed with anti-TRb as described in Materials and
Methods. Immunoprecipitates were analyzed by quantitative PCR using
primers that flanked the distal TREs or proximal DR-4 (LXRE) as indicated
at the top of the figure. Results are expressed as a fold change in comparing
the level of DNA amplification specifically precipitated by the TR-b antibody
relative to that precipitated by a normal mouse IgG as control. The
recruitment of TRb to a non-relevant region of the genome in the YY1 locus
is shown as an additional negative control. The data represent the mean of
triplicates for two individual experiments and include error bars.
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ary effects that result from the loss of TRa.
Using synthetically designed promoter constructs, a con-
sensus DR-4 element was shown to be a potent TRE (16).
However, as mentioned above, TREs found in natural
promoters are quite diverse in sequence, and the number
and orientation of the individual half sites are variable
(17–21). TRE1 contains only a mutation sensitive single
TR half site. In vitro protein–DNA-binding assays in the pre-
sent studies revealed that both of the TREs bind to TR/RXR
heterodimers and no signiﬁcant binding of monomers or
homodimers of TR or RXR was detected (Figure 3). An
extensive mutagenesis analysis failed to identify a crucial
second half site for TRE1 (data not shown). The TRE2 is a
DR0 which is similar to the TRE of the PEPCK (18).
Although TR can bind to TRE as a monomer, homodimer
or heterodimer with RXR (15,42–46), it is likely that the
TR/RXR heterodimer binds to the TRE preferentially to
mediate T3 response in vivo because both TR and RXR
were required for efﬁcient binding and both TR and RXR
are required for activation as shown in other studies (18,21).
The two TRE’s identiﬁed here in the rat CYP7A1 are con-
served in the mouse promoter eventhough the surrounding
sequence is not highly conserved, suggesting there is evolu-
tionary pressure to preserve the T3 response in these two spe-
cies. In an earlier study, expression of the human CYP7A1
gene was not stimulated by T3 (47). Additionally, the distal
TR-binding sites we identiﬁed in the murine promoters do
not seem to be conserved in the human gene and expression
of a human transgene containing a large segment of 50 ﬂank-
ing DNA in mice was not regulated by T3 (48). Additionally,
the proximal DR-4 (LXRE) is not conserved in the human
gene (49) and if anything, the human CYP7A1 may in fact
be negatively regulated by T3 (50) through a putative negat-
ive TRE at  227 to  247 in the promoter. Taken in total, the
data suggest there are signiﬁcant species differences in the
effects of thyroid hormone on lipid metabolism that need to
be explored further.
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